Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression. Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its […]
DaltonTx, a UK-based technology company, today announces its exit from from stealth and the completion of a £4 million seed financing round to build adaptive, AI-enabled discovery platforms that reshape the economics, timelines, and outcomes of R&D so breakthrough medicines reach patients faster. AI offers pharma a unique opportunity to discover medicines more effectively and […]
The big buzz around AI in healthcare is the potential it holds to identify and even create new drugs. “AI drug discovery” is the great new hope. And – despite critics awkwardly pointing out that no AI-generated drugs have yet been approved by any regulator, and vanishing few appear to be close to that finishing […]
Delivers high-performing AI infrastructure through NVIDIA DGX Cloud Lepton to portfolio companies, creating a powerful competitive advantage in $100B+ life sciences market BioCorteX, Bioptimus, Cure51, and Latent Labs among first cohort of startups to gain GPU capacity credits, helping position Europe at forefront of AI-driven drug discovery revolution PARIS, France – June, 11, 2025 – […]
Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases Continues strong momentum following 2024 emergence from stealth with $10M seed financing Dundee, Scotland – 13 January […]
